PNs, ORNs and LNs response to a short (50 ms) pulse, similar results of Fig 4. by Mario Pannunzi (553941)

Trend of temperature decrease in thermogradient freezer during the night from 7:00 P.M. to 5:00 A.M. by Alireza Hasanfard (13919335)

Bumblebees were subjected to 5 day exposure to Imidacloprid and/or/none twice daily 670 nm. by Michael Barry Powner (11337243)

“…As with respiration we then asked what 670nm duration was needed for correction B. Bumblebees (≥ 20 bees per group) maintained on Imidacloprid were exposed to 670nm light for 0.5, 1, 5, 15 or 60mins. …”

Comparison of the decrease of CFU in CSF and blood between treatment groups within the first 6 h after treatment. by Luca G. Valente (12463057)

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

MBIC50 and MBEC50 values (µg/mL) of synthesized 1,2,3,5-tetrazine derivatives against bacteria pathogen strains. by Jean Paul Dzoyem (6424445)

Subjects:

Differential gene expression assay EC₅₀ values in Huh-7 cells and PHH. by Xuan G. Luong (9761423)

Differential protective effects of a history of thyroid cancer on breast cancer-specific mortality in patients at age<50years and age≥50years at the diagnosis of breast cancer. by Weiwei Cheng (582223)

KDM6A mRNA expression is decreased in PTFE mice. by Simon Lebek (9756148)

Exercise test characteristics for identifying stenosis ≥ 50% in any limb among the 60 limbs with normal ABIs (> 0.91). by O. Stivalet (6890189)

Kylo-0603’s EC50 & tissue levels. by Xueqin lu (22250795)

Reference mutations versus background noise across replicates. by Lizhi Yu (12476136)

Analytical sensitivity and reproducibility. by Lizhi Yu (12476136)

Depth of coverage and heterogeneity of the mutation loci. x-axis, mutation loci in sample set one or two; y-axis, depth of coverage after UMI consolidation. by Lizhi Yu (12476136)

Quantification and accuracy of average VAF. by Lizhi Yu (12476136)

Schematic overview of the cross-platform study. by Lizhi Yu (12476136)

Impact of DNA extraction process on depth of coverage. by Lizhi Yu (12476136)